Industry
Biotechnology
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Loading...
Open
8.43
Mkt cap
446M
Volume
324K
High
8.78
P/E Ratio
-2.33
52-wk high
11.60
Low
8.18
Div yield
N/A
52-wk low
2.19
Portfolio Pulse from
December 10, 2024 | 5:00 pm
Portfolio Pulse from
November 25, 2024 | 4:15 pm
Portfolio Pulse from
November 15, 2024 | 4:00 pm
Portfolio Pulse from
November 14, 2024 | 9:15 pm
Portfolio Pulse from
November 11, 2024 | 11:30 am
Portfolio Pulse from Benzinga Newsdesk
September 24, 2024 | 10:52 am
Portfolio Pulse from Benzinga Newsdesk
September 05, 2024 | 10:50 am
Portfolio Pulse from Benzinga Newsdesk
August 14, 2024 | 8:10 pm
Portfolio Pulse from Benzinga Newsdesk
May 15, 2024 | 8:20 pm
Portfolio Pulse from Benzinga Newsdesk
April 04, 2024 | 3:17 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.